Key result
The antiangiogenic herbal composition Ob-X reduced visceral fat by 20.5% from baseline over 12 weeks, a reduction 1.9 times greater than placebo.
Why the study?
Does the antiangiogenic herbal composition Ob-X reduce visceral fat in abdominally obese subjects?
RCT (n=80)
Double-blind
randomized
Does the antiangiogenic herbal composition Ob-X reduce visceral fat in abdominally obese subjects?
The antiangiogenic herbal composition Ob-X significantly reduces visceral fat in abdominally obese subjects over 12 weeks.
Answers are grounded in this paper and cite their sources.
May support Ob-X as adjunct for visceral fat reduction; extends antiangiogenic herbal evidence to human metabolic trials.
Adipose tissue growth is angiogenesis‐dependent, and angiogenesis inhibitors can regulate adipose tissue mass by cutting off the blood supply. We examined whether antiangiogenic herbal composition Ob‐X can reduce fast‐growing abdominal fat, especially visceral fat in humans by inhibiting angiogenesis. Eighty abdominally obese subjects (body mass index: 25‐29.9 kg/m 2 , waist circumference: exceeding 90 cm for males and 85 cm for females) participated in a 12‐week randomized, double‐blind, placebo‐controlled human study to evaluate the efficacy and safety of Ob‐X. 690 mg of Ob‐X was administered orally twice a day. The Ob‐X group showed a noticeable reduction in visceral fat of 20.5% after the 12‐week treatment as compared to baseline measured by computed tomography. The change in visceral fat in the Ob‐X group was statistically significant as compared to the placebo group (p = 0.0495) and 1.9 times higher than in the placebo group. Therefore, angiogenesis inhibitor Ob‐X has the potential to improve obesity‐related metabolic syndrome by reducing dangerous visceral fat.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2018) conducted an RCT in Abdominal obesity (n=80). Ob-X vs. Placebo was evaluated on Change in visceral fat (p=0.0495). The antiangiogenic herbal composition Ob-X reduced visceral fat by 20.5% from baseline over 12 weeks, a reduction 1.9 times greater than placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: